Response to high-dose ifosfamide in patients with advanced/recurrent ewing sarcoma

Pediatric Blood and Cancer

Volumn 52, Issue 5, 2009, Pages 581-584

  Ferrari, S ^a   Del Prever, A Brach ^b   Palmerini, E ^a   Staals, E ^a   Berta, M ^b   Balladelli, A ^a   Picci, P ^a   Fagioli, F ^b   Bacci, G ^a   Vanel, D ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

Author keywords

Ewing sarcoma family tumors; High dose ifosfamide; Radiographic response; Toxicity

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; MESNA; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADOLESCENT; ADULT; ADVANCED CANCER; ARTICLE; BRAIN TOXICITY; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG MEGADOSE; EWING SARCOMA; FEMALE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT CANCER; SCHOOL CHILD; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR GROWTH; CANCER STAGING; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; FEMALE; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; NEOPLASM STAGING; RECURRENCE; SARCOMA, EWING'S;

EID: 63649140230     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21917     Document Type: Article

References (21)

1. Bernstein M, Kovar H, Paulussen M, et al. Ewing's sarcoma family of tumors: Current management. Oncologist 2006;11:503- 519.
2. Bielack SS, Carrle D, Hardes J, et al. Bone tumors in adolescents and young adults. Curr Treat Options Oncol 2008;9:67-80.
3. Paulussen M, Ahrens S, Dunst J, et al. Localized Ewing tumor of bone: Final results of the cooperative Ewing's sarcoma study CESS 86. J Clin Oncol 2001;19:1818-1829.
4. Grier HE, Krailo MD, Tarbel NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003; 348:694-701.
5. Bacci G, Forni C, Longhi A, et al. Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and1992. Eur J Cancer 2004;40:73-83.
6. Bacci G, Ferrari S, Longhi A, et al. Therapy and survival after recurrence of Ewing's tumors: The Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol 2003;14:1654-1659.
7. Leavey PJ, Mascarenhas L, Marina N, et al. Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the children's oncology group. Pediatr Blood Cancer 2008;51:334-338.
8. Elias AD, Eder JP, Shea T, et al. High-dose ifosfamide with mesna uroprotection: A phase I study. J Clin Oncol 1990;8:170-178.
9. Patel SR, Vadhan-Raj S, Papadopolous N, et al. High-dose ifosfamide in bone and soft tissue sarcomas: Results of phase II and pilot studies -Dose-response and schedule dependence. J Clin Oncol 1997;15:2378-2384.
10. Le Cesne A, Antoine E, Spielmann M, et al. High-dose ifosfamide: Circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995;13:1600-1608.
11. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;3:205-216.
12. Simon R, White RE. Methodologic guidelines for reports of clinical trials. Cancer Treat Rep 1985;69:1 -3.
13. Rosito P, Mancini AF, Rondelli R, et al. Italian cooperative study for the treatment of children and young adults with localized Ewing sarcoma of bone: A preliminary report of 6 years of experience. Cancer 1999;86:421-428. Erratum in: Cancer. 2005; 104: 667.
14. Ferrari S, Alvegard T, Luksch R, et al. Non-metastatic Ewing's family tumors: High-dose chemotherapy with stem cell rescue in poor responder patients. Preliminary results of the Italian/ Scandinavian ISG/SSG III protocol. J Clin Oncol 2007;25:10014. 2007 ASCO Annual Meeting Proceedings Part I (June 20 Supplement).
15. Kupfer A, Aeschlimann C, Wermuth B, et al. Prophylaxis and reversal of ifosfamide encephalopathy with methylene blue. Lancet 1994;343:763-764.
16. Wagner LM, McAllister N, Goldsby RE, et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 2007;48:132-139.
17. Hunold A, Weddeling N, Paulussen M, et al. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer 2006;47:795-800.
18. Bernstein ML, Devidas M, Lafreniere D, et al. Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric oncology group/children's cancer group phase II study 9457-A report from the children's oncology group. J Clin Oncol 2006;24:152-159.
19. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: Analysis of975 patients from the European intergroup cooperative Ewing's sarcoma study group. J Clin Oncol 2000;18:3108-3114.
20. Bacci G, Ferrari S, Bertoni F, et al. Prognostic factors in non- metastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: Analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol 2000;18:4-11.
21. Ferrari S, Bertoni F, Palmerini E, et al. Predictive factors of histologic response to primary chemotherapy in patients with Ewing sarcoma. J Pediatr Hematol Oncol 2007;29:364-368.